Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharma LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +7.50p +1.39% 547.50p 540.00p 555.00p 550.00p 540.00p 540.00p 8,240.00 15:18:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.4 -4.5 -22.1 - 151.84

Faron Pharma Share Discussion Threads

Showing 1 to 13 of 25 messages
Chat Pages: 1
DateSubjectAuthorDiscuss
15/3/2017
09:37
Most a probably amazed at the rise and stunned to comment! Which I was in at 250p just a short time ago!
lauders
15/3/2017
09:11
Vacuum of sellers, my best guess. Did anyone attempt to figure out what might traumakine be worth upon a positive P3 outcome?
dacian
14/3/2017
17:46
Not much comment here... considering the rocket.
capt bligh
14/3/2017
17:45
Not much comment here... considering the rocket.
capt bligh
02/3/2017
12:44
Hi Lauders, don't think the chart has much relevance at this stage but nevertheless, it does look pretty at the top of the thread. What made me invest in Faron, (apart from Apad :-) )were the traumakine potential and the ceo. Dr Jalkanen seems the sort of honest, capable and shareholder friendly kind of guy, my gut feeling tells me. But first the bear case: very simple, if traumakine fails to get MA (marketing authorisation) then a 50% share price dive ( my best guess) will promptly happen within the first 5 min of the trading day. I have no doubt about that. The bull case is a bit more complicated, but the more I read about it the more I think the conversation now is how well will this product sell. In my view, the MA is in the bag , main reason being the bar was lowered to 50% and in Phase 2 they achieved 80% ( reduction in mortality rates). Many drugs make it through the P3 stages but simply don't sell, or if there is a genuine blockbuster out there ( blue sky, billion with a B! sales potential ) it gets gobbled up by the big boys after Phase 2, generally. If traumakine achieves anywhere near the 80% reduction in mortality rates as per P2 trials then I can't see how a doctor can justify not using a drug like that where 30-40% of the ards patients die. Only if the drug is effective and makes a meaningful difference, then it will be a financial success as well. I think there is a realistic , good chance of that happening with traumakine. Not a blockbuster, but a realistic chance of success. How successful ?!... it depends how good the drug will prove to be.
dacian
02/3/2017
08:50
Many thanks capt bligh! Much better. Pretty impressive chart at the moment!
lauders
01/3/2017
15:18
Any chance of some charts here capt bligh? Please :-) Interested in following FARN too.
lauders
28/2/2017
08:41
interesting rns
capt bligh
09/2/2017
20:38
Today's update reads much better face to face: Http://www.stocktube.com/video/6892/faron-pharmaceuticals-to-build-on-success-of-extremely-exciting-2016-6892.html
dacian
03/2/2017
21:09
Thanks for starting the thread. Been a keen follower over the last two months.
longshanks
31/1/2017
20:06
The attraction here is that THEY HAVE THE PATENT
saturn5
28/1/2017
14:45
Thanks for opening the fan club capt bligh, I couldn't resist the privilege of writing the first post. There's the best summary that I could find on Faron: Http://cordis.europa.eu/result/rcn/184021_en.html and their product traumakine Http://www.traumakine.eu/
dacian
27/1/2017
11:39
Saw a presentation last night ...was impressed and bought... anyone else?
capt bligh
Chat Pages: 1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170328 04:25:53